10-K: Helius Medical Technologies Reports 2024 Results, Navigates Reimbursement Challenges

Helius Medical Technologies announces its 2024 financial results, highlighting progress in commercialization and regulatory efforts while addressing ongoing reimbursement hurdles.

Summary

• Helius Medical Technologies reported a net loss of $11.7 million for the year ended December 31, 2024, compared to a net loss of $8.9 million in the previous year.
• Revenue for 2024 was $0.5 million, primarily from product sales in the U.S. and Canada.
• The company is focused on commercializing its PoNS device for gait deficit due to MS and is pursuing regulatory approvals for other indications.
• Helius is facing challenges in obtaining adequate reimbursement rates from CMS for the PoNS device.
• The company is exploring various financing options to fund its operations beyond the second quarter of 2025.
• Helius completed the transition of PoNS device manufacturing to Minnetronix, Inc.
• The company is conducting clinical trials for stroke and is targeting an FDA submission in mid-to-late 2025.
• Helius is also assessing the feasibility of a clinical program for mmTBI if nondilutive financing becomes available.
• The company is working to make the PoNS device available to federal healthcare systems through partnerships.
• Helius is facing potential delisting from The Nasdaq Capital Market due to non-compliance with minimum bid price and stockholders' equity requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as partnerships and regulatory progress, the financial results are concerning, and the company faces significant challenges in obtaining reimbursement and maintaining its Nasdaq listing. The going concern warning from the auditor further dampens the sentiment.

Positives

• Received HCPCS codes for PoNS device components, which became effective April 1, 2024.
• Partnered with Lovell Government Services to make PoNS available to federal healthcare systems.
• Completed enrollment in stroke registrational program, targeting FDA submission in 2025.
• Completed transition of PoNS device manufacturing to Minnetronix, Inc.
• Received first third-party reimbursement from a major insurance carrier at a 7% rebate.
• Entered into warrant exercise inducement offer letters generating gross proceeds of $3.7 million.

Negatives

• Reported a net loss of $11.7 million for 2024.
• Facing challenges in obtaining adequate reimbursement rates from CMS.
• Revenue decreased compared to the previous year.
• Facing potential delisting from The Nasdaq Capital Market due to non-compliance with minimum bid price and stockholders' equity requirements.
• Independent registered public accounting firm has included an explanatory paragraph relating to the company's ability to continue as a going concern in its report on the audited financial statements.

Risks

• The company may not achieve or sustain profitability in the future.
• Failure to obtain additional financing may cause the business to fail.
• Global macroeconomic instability could adversely affect the ability to raise additional financing.
• Limited market awareness of the PoNS device and the neuromodulation market.
• Dependence on third parties for manufacturing and distribution.
• Inadequate intellectual property protection could allow competitors to gain access to the technology.
• Potential product liability claims and insufficient product liability insurance.
• Failure to comply with healthcare laws could result in substantial penalties.
• Cybersecurity incidents could disrupt business operations and compromise sensitive data.
• The company continues to disagree with CMS pricing determinations for both the Controller and Mouthpiece and plans to continue to challenge the pricing decisions through avenues available including the individual claims appeal process.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future and will require additional funding to continue operations. The company is targeting an FDA submission for stroke in the second quarter of 2025, with the plan to achieve FDA authorization by the end of 2025.

Industry Context

The neurostimulation market is predominantly comprised of surgically implanted, invasive technologies. Helius believes it has a first-mover advantage in the non-implantable neurostimulation space. The company faces competition from larger, publicly traded companies with more resources.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• The document mentions Ampyra (dalfampridine) as a drug approved by FDA and Heath Canada, which is indicated for the improvement of gait speed in conjunction with physical therapy in patients with MS, offers the closest, albeit limited only to speed, comparison to PoNS Therapy on improvement in gait.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the need for additional financing.
• Employees' job security may be affected by the company's financial performance and ability to continue operations.
• Customers may experience uncertainty regarding the availability and affordability of the PoNS Therapy due to reimbursement challenges.
• Suppliers and creditors may face increased risk due to the company's financial situation and going concern uncertainty.

Next Steps

• Continue commercialization efforts for the PoNS device in the U.S. and Canada.
• Pursue regulatory approvals for additional indications, including stroke and mmTBI.
• Negotiate coverage and reimbursement with third-party payers.
• Explore various financing options to fund operations.
• Challenge CMS pricing determinations for the PoNS Controller and Mouthpiece.
• Continue to monitor and address Nasdaq listing requirements.

Key Dates

Keywords

PoNS, Helius Medical Technologies, gait deficit, neuromodulation, MS, stroke, mmTBI, reimbursement, FDA, clinical trials, Medicare, CMS, manufacturing, commercialization, intellectual property